Antitumor Activity of an EpCAM/CD3-bispecific BiTE Antibody During Long-term Treatment of Mice in the Absence of T-cell Anergy and Sustained Cytokine Release-Reference-Cited by-同舟云学术

Antitumor Activity of an EpCAM/CD3-bispecific BiTE Antibody During Long-term Treatment of Mice in the Absence of T-cell Anergy and Sustained Cytokine Release

Published:2009-06 Issue:5 Volume:32 Page:452-464
ISSN:1524-9557
Container-title:Journal of Immunotherapy
language:en
Short-container-title:

Author:

Amann Maria,dÁrgouges Sandrine,Lorenczewski Grit,Brischwein Klaus,Kischel Roman,Lutterbuese Ralf,Mangold Susanne,Rau Doris,Volkland Jörg,Pflanz Stefan,Raum Tobias,Münz Markus,Kufer Peter,Schlereth Bernd,Baeuerle Patrick A.,Friedrich Matthias

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology,Immunology,Immunology and Allergy

Reference37 articles.

1. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma;Dudley;J Clin Oncol,2005

2. Immunosuppressive strategies that are mediated by tumor cells;Rabinovich;Annu Rev Immunol,2007

3. High frequency of functionally active Melan-a-specific T cells in a patient with progressive immunoproteasome-deficient melanoma;Meidenbauer;Cancer Res,2004

4. Bispecific antibodies in cancer therapy;Weiner;Cancer J,2000

5. Recombinant bispecific antibodies for cancer therapy;Kontermann;Acta Pharmacol Sin,2005

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hyperthermia in Combination with Emerging Targeted and Immunotherapies as a New Approach in Cancer Treatment;Cancers;2024-01-24

2. Lung Cancer Stem Cell Markers as Therapeutic Targets: An Update on Signaling Pathways and Therapies;Frontiers in Oncology;2022-05-26

3. IgG-like Bispecific Antibody CD3×EpCAM Generated by Split Intein Against Colorectal Cancer;Frontiers in Pharmacology;2022-02-23

4. For whom the T cells troll? Bispecific T-cell engagers in glioblastoma;Journal for ImmunoTherapy of Cancer;2021-11

5. The old CEACAMs find their new role in tumor immunotherapy;Investigational New Drugs;2020-06-02